Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ugo De Giorgi

Showing results (1-10 of 505) with videos related to

Pageof 51
Sort By:
Future Oncology (London, England)|July 19, 2013
Value of pharmacokinetic studies for patients with gastrointestinal stromal tumorsUgo De Giorgi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2007
KIT mutations and imatinib dose effects in patients with gastrointestinal stromal tumorsUgo De Giorgi
Molecular Cancer Therapeutics|March 16, 2005
Imatinib and gastrointestinal stromal tumors: Where do we go from here?Ugo De Giorgi, Jaap Verweij
Tumori|May 7, 2002
Polychemotherapy in overseventy breast cancer patientsMaurizio Marangolo, Ugo De Giorgi
The Lancet. Oncology|May 13, 2018
[<sup>177</sup>Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet?Giovanni Paganelli, Ugo De Giorgi
La Tunisie Medicale|January 25, 2006
High dose chemotherapy in germ cell tumorsGiovanni Rosti, Ugo De Giorgi
The Lancet. Oncology|November 2, 2013
Salvage treatment of relapsed or refractory germ-cell tumoursUgo De Giorgi, Dino Amadori
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2011
Dose intensification in hormone receptor-negative and/or human epidermal growth factor receptor 2-negative high-risk primary breast cancerUgo De Giorgi, Dino Amadori
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2010
[18F]Fluorodeoxyglucose positron emission tomography for outcome prediction of mammalian target of rapamycin inhibitor therapyUgo De Giorgi, Dino Amadori
The Lancet. Oncology|August 13, 2021
Talazoparib: a new biomarker-directed therapy in advanced prostate cancerVincenza Conteduca, Ugo De Giorgi
Pageof 51

Showing results (1-10 of 505) with videos related to

Sort By:
Pageof 51
Future Oncology (London, England)|July 19, 2013
Value of pharmacokinetic studies for patients with gastrointestinal stromal tumorsUgo De Giorgi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2007
KIT mutations and imatinib dose effects in patients with gastrointestinal stromal tumorsUgo De Giorgi
Molecular Cancer Therapeutics|March 16, 2005
Imatinib and gastrointestinal stromal tumors: Where do we go from here?Ugo De Giorgi, Jaap Verweij
Tumori|May 7, 2002
Polychemotherapy in overseventy breast cancer patientsMaurizio Marangolo, Ugo De Giorgi
The Lancet. Oncology|May 13, 2018
[<sup>177</sup>Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet?Giovanni Paganelli, Ugo De Giorgi
La Tunisie Medicale|January 25, 2006
High dose chemotherapy in germ cell tumorsGiovanni Rosti, Ugo De Giorgi
The Lancet. Oncology|November 2, 2013
Salvage treatment of relapsed or refractory germ-cell tumoursUgo De Giorgi, Dino Amadori
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2011
Dose intensification in hormone receptor-negative and/or human epidermal growth factor receptor 2-negative high-risk primary breast cancerUgo De Giorgi, Dino Amadori
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2010
[18F]Fluorodeoxyglucose positron emission tomography for outcome prediction of mammalian target of rapamycin inhibitor therapyUgo De Giorgi, Dino Amadori
The Lancet. Oncology|August 13, 2021
Talazoparib: a new biomarker-directed therapy in advanced prostate cancerVincenza Conteduca, Ugo De Giorgi
Pageof 51